Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
Clinical trial NCT03787602 · UNKNOWN
Trial details
- NCT number
- NCT03787602
- Sponsor
- Kartos Therapeutics, Inc.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-19
- Primary completion
- 2024-11-01
- Enrollment
- 115
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.